Financial Performance - Revenue increased by 124.9% year-on-year to HKD 126,414,000 compared to HKD 56,202,000 in the same period last year[3][9] - The group's underlying recurring profit surged by 659.0% to HKD 59,054,000 from HKD 7,779,000 year-on-year[3][11] - Reported profit for the first half of 2023 was HKD 55,993,000, a significant turnaround from a loss of HKD 2,207,000 in the same period last year[4][10] - Earnings per share for reported profit was HKD 0.18, compared to a loss of HKD 0.007 per share in the previous year[10] - Total comprehensive income attributable to owners for the period was approximately HKD 71,899,000, compared to a loss of HKD 12,418,000 in the previous year[12] - The company reported a profit of HKD 2,750,000 in the financial investment segment, compared to a loss of HKD 4,110,000 in 2022[20] - The group recorded a net revaluation loss of HKD 5,293,000 for investment properties in the UK, compared to a loss of HKD 4,101,000 for the same period last year[31] - The operating profit for the period was HKD 68,297, compared to HKD 1,189 in the previous year, indicating a substantial improvement[47] - The group reported a profit of HKD 55,993 for the period, a significant recovery from a loss of HKD 2,207 in the same period last year[47] - The total comprehensive income attributable to the company's owners for the six months ended June 30, 2023, was HKD 71,899,000, compared to a loss of HKD 12,418,000 in the same period of 2022[103] Revenue Segmentation - The healthcare segment generated revenue of HKD 120,942,000, reflecting a 128.0% increase from the previous year's figures[9][11] - The property investment segment reported revenue of HKD 4,334,000, up 39.0% from the previous year[9][11] - The financial investment segment saw a dramatic increase in revenue to HKD 1,138,000, a rise of 3,824.1% year-on-year[9][11] - Healthcare segment revenue increased by 128.0% to HKD 120,942,000 compared to HKD 53,055,000 in 2022[13] - Profit from the healthcare segment surged by 296.7% to HKD 73,666,000 from HKD 18,571,000 in 2022[13] - Property investment revenue increased by 39.0% to HKD 4,334,000 from HKD 3,118,000 in 2022[16] - Income from financial investments surged by 3,824.1% to HKD 1,138,000 from HKD 29,000 in 2022[19] Market Performance - Sales in the Chinese market rose by 176.2%, driven by the reopening of cross-border travel and improved consumer sentiment[13] - Southeast Asia sales grew significantly, attributed to aggressive advertising campaigns in the Philippines and strong performance in Singapore[14] - The company expects continued sales momentum in the Chinese market for the remainder of the fiscal year[5] - The company anticipates continued sales momentum in the Chinese market for the remainder of the year, driven by strong local demand and a tight labor market in Hong Kong[88] Assets and Liabilities - The group’s total assets as of June 30, 2023, amounted to HKD 913,561, an increase from HKD 823,136 at the end of the previous year[43] - The group’s total liabilities were reported at HKD 115,911, compared to HKD 96,840 at the end of the previous year, indicating an increase in financial obligations[43] - The group’s total liabilities included bank borrowings due within one year amounting to HKD 5,488,000 as of June 30, 2023, slightly down from HKD 5,496,000 as of December 31, 2022[62] - The total accounts payable and other payables as of June 30, 2023, amounted to HKD 14,501,000, an increase from HKD 12,231,000 as of December 31, 2022[63] Cash Flow and Dividends - The net cash generated from operating activities for the six months ended June 30, 2023, was HKD 61,051,000, compared to HKD 8,685,000 in the same period of 2022[110] - The company paid dividends amounting to HKD 17,452,000 during the reporting period[109] - The company declared an interim dividend of HKD 0.03 per share and a special interim dividend of HKD 0.055 per share, totaling HKD 26,489,000, compared to HKD 7,168,000 in the previous year[70] - The company proposed a final dividend of HKD 0.038 per share, totaling HKD 11,842,000, and a special dividend of HKD 0.03 per share, totaling HKD 9,349,000, which was approved by shareholders on June 7, 2023[125] Employee and Operational Metrics - Employee costs increased by 9.3% to HKD 18,746,000 from HKD 17,158,000 in 2022[23] - The workforce increased to 99 employees as of June 30, 2023, up from 95 employees at the end of 2022, indicating growth in operational capacity[87] - New machinery will be purchased and installed to enhance production capacity in response to market demand[88] Financial Management - The group’s financial costs decreased slightly to HKD 434 from HKD 457 in the previous year, showing improved cost management[44] - Other operating expenses decreased by 17.6% to HKD 10,849,000 compared to HKD 13,166,000 in 2022, reflecting a lower percentage of total revenue at 8.6% versus 23.4% in 2022[54] - The company has maintained sufficient cash and marketable securities to meet its short-term liabilities and operational needs[83] Governance and Compliance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange rules and has complied with the code provisions during the reporting period, except for certain deviations[141] - The audit committee, composed of three independent non-executive directors, reviewed the interim financial information for the six months ended June 30, 2023[143] - The company has ensured that external auditors are present at the annual general meeting to address questions regarding audit work and independence, although unforeseen events prevented their attendance at the last meeting[142] - The company confirmed that all directors complied with the standards set out in the securities trading code during the reporting period[143]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 PAK FAH YEOW INTERNATIONAL LIMITED 白 花 油 國 際 有 限 公 司 * （於百慕達註冊成立之有限公司） （股份代號：239） 截至二零二三年六月三十日止六個月之中期業績公佈 摘要 • 收入按年上升124.9%。 • 本集團之表現指標－基礎經常性溢利按年上升659.0%，反映出醫療保健業 務之銷售收入大幅增長。 • 於二零二三年上半年錄得報告溢利，而二零二二年同期則錄得報告虧損。 • 預計中國市場於本年度剩下時間仍將保持銷售勢頭。 ...

Financial Performance - Revenue for the year 2022 was HKD 147,200,000, an increase of 5.4% compared to HKD 139,823,000 in 2021[173]. - Operating profit decreased to HKD 38,414,000 in 2022 from HKD 47,489,000 in 2021, representing a decline of 19.4%[173]. - Profit attributable to owners of the company was HKD 29,955,000 in 2022, down 21.5% from HKD 38,186,000 in 2021[173]. - The company reported a net loss from fair value changes of financial assets at fair value through profit or loss of HKD 2,465,000 in 2022, compared to a gain of HKD 1,954,000 in 2021[173]. - Total comprehensive income attributable to owners of the company was HKD 24,123,000 in 2022, a decrease of 56.2% from HKD 55,098,000 in 2021[174]. - Basic and diluted earnings per share for 2022 were 9.6 HK cents, down from 12.3 HK cents in 2021[174]. - Non-current assets totaled HKD 609,453,000 in 2022, a slight decrease from HKD 631,310,000 in 2021[181]. - Current assets increased to HKD 213,683,000 in 2022 from HKD 206,439,000 in 2021[181]. - The company’s total equity remained stable at HKD 707,225,000 in 2022, compared to HKD 707,722,000 in 2021[181]. - Cash and cash equivalents at year-end were HKD 169,441,000, up from HKD 164,660,000 in 2021[181]. - For the year ended December 31, 2022, the company reported a total comprehensive income attributable to owners of the company of HKD 24,123,000, compared to HKD 29,955,000 in the previous year, reflecting a decrease of approximately 19.5%[187]. - The net cash generated from operating activities for the year was HKD 39,920,000, a decline of 43.3% from HKD 70,358,000 in 2021[188]. - The company’s total cash and cash equivalents at the end of the year amounted to HKD 169,441,000, an increase from HKD 164,660,000 at the beginning of the year[188]. - The company declared a final dividend of HKD 11,842,000 and a special dividend of HKD 9,349,000 for the year, totaling HKD 21,191,000 in dividends declared[187]. - The company incurred a net cash outflow from financing activities of HKD 33,906,000, compared to HKD 22,406,000 in the previous year, indicating an increase in financing costs[188]. - The company’s total equity attributable to owners increased to HKD 691,643,000 from HKD 692,140,000, showing a slight decrease of 0.07%[187]. - The company’s revenue from operations was not explicitly detailed in the provided documents, indicating a need for further analysis on revenue generation[187]. - The company reported a decrease in cash received from dividends to HKD 109,000 from HKD 169,000 in the previous year, reflecting a decline of approximately 35.5%[188]. - The company’s interest paid increased to HKD 364,000 from HKD 287,000, representing a rise of 26.9%[188]. - The company’s total assets and liabilities were not detailed in the provided documents, suggesting a need for additional financial metrics to assess overall financial health[187]. Governance and Board Structure - The board consists of three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balance of power[19]. - The board has established effective mechanisms to ensure independent opinions and data are available for decision-making[22]. - In 2022, the board held approximately four meetings, with all directors attending all meetings except for two newly appointed independent directors[27]. - The company has a clear governance structure, with the chairman and CEO roles separated to maintain accountability[18]. - The board reviews and monitors compliance with legal and regulatory requirements regularly[24]. - The company has implemented a training program for directors to enhance their understanding of their responsibilities and the business environment[26]. - The company’s governance policies and practices are regularly reviewed to ensure they meet current standards and stakeholder expectations[25]. - The board is responsible for the overall strategy and direction of the company, focusing on long-term value creation[29]. - Two independent non-executive directors, Huang Yingqi and Ye Tianci, resigned effective September 30, 2022, after serving over nine years[33]. - The Audit Committee, composed of three independent non-executive directors, held three meetings in 2022[42]. - The Remuneration Committee reviewed and approved the remuneration of individual executive and non-executive directors, as well as senior management, during 2022[44]. - The Nomination Committee evaluated the independence of independent non-executive directors and reviewed the board's structure and composition[51]. - As of December 31, 2022, the board consisted of six male members and one female member, with a commitment to reviewing gender diversity annually[54]. - The company emphasizes a balanced and diverse board to enhance governance and effectiveness, considering various skills and backgrounds[53]. - The Audit Committee's responsibilities include reviewing financial reports and ensuring the independence of auditors[38]. - The company aims to maintain effective communication between the executive team and the board to ensure awareness of major business developments[35]. - The Remuneration Committee recommended annual remuneration policies to the board, ensuring transparency in the process[44]. - The company has established a clear division of responsibilities between the Chairman and the CEO to maintain a balance of power[34]. - The company has adopted a board diversity policy aimed at establishing a diverse board composition[58]. - The nomination committee is responsible for identifying and nominating candidates for the board, ensuring a diverse skill set and experience among board members[59]. - The company has a policy in place to ensure that the board is not composed of a single gender, promoting gender diversity[60]. - The board will review the dividend policy as necessary to ensure its effectiveness[65]. - The company has appointed external secretarial services, with Mr. Lo Tai On serving as the company secretary[67]. - The nomination committee has confirmed the suitability and effectiveness of the board diversity and nomination policies[63]. - The board is responsible for assessing and determining the nature and extent of risks faced by the group, with a review conducted at least annually[72]. - Risk identification is based on surveys conducted by senior management across departments, covering both internal and external risks, including strategic, operational, financial, compliance, and environmental, social, and governance risks[72]. - A risk assessment report is submitted to the audit committee and the board, detailing the main risks and corresponding action plans to mitigate these risks[84]. - The internal audit function has been approved for a three-year plan, which includes identifying major control measures and testing their effectiveness[81]. - The company has adopted an anti-corruption policy to ensure the highest standards of integrity and ethical conduct in its operations[85]. - The board reviews the adequacy of human resources in accounting and financial reporting departments, ensuring sufficient qualified staff and training budgets[87]. - The company emphasizes timely and accurate disclosure of significant information, adhering to a policy regarding the disclosure of inside information[80]. - The board has confirmed the effectiveness of the risk management mechanisms and internal control systems as of December 31, 2022[88]. Shareholder Communication and Engagement - The company encourages shareholder participation in annual general meetings, with the next meeting scheduled for June 7, 2023[91]. - The company maintains good communication with shareholders through various formal channels, including interim reports and announcements[90]. - The board reviewed the implementation and effectiveness of the shareholder communication policy annually, which aims to enhance timely and transparent communication with shareholders[102]. - The company’s main business is investment holding, with details of subsidiaries' operations disclosed in the financial statements[102]. - The company has maintained a public float of at least 25% of its issued shares, in compliance with listing rules[147]. - The company has not entered into any arrangements for the acquisition of shares or bonds that would benefit its directors during the year[137]. - The company has extended Mr. Yan Wei Shan's appointment for three years as of June 18, 2022[135]. - The company has not signed any management or administrative contracts regarding its main business operations during the year[151]. Investment Properties and Financial Assets - As of December 31, 2022, the group's total investment properties in the UK amounted to approximately HKD 110 million, down from HKD 125.3 million in 2021[2]. - The company’s borrowing currency is primarily GBP, with a foreign exchange risk of approximately HKD 104,500,000 related to the value of UK investment properties[112]. - The fair value of investment properties and leased land and buildings held by the company as of December 31, 2022, is recorded at HKD 264,937,000 and HKD 334,700,000 respectively[158]. - The company relies on independent professional valuers in the UK, Singapore, and Hong Kong to estimate the fair value of its investment properties and leased land and buildings, which involves significant estimates and judgments[158]. - The audit procedures included assessing the competence and objectivity of the valuers, as well as verifying the input data used in the valuation process[158]. - The company is responsible for preparing financial statements that present a true and fair view in accordance with Hong Kong Financial Reporting Standards[164]. - The auditors are tasked with identifying and assessing risks of material misstatement in the financial statements due to fraud or error, and designing appropriate audit procedures[168]. - The auditors evaluate the appropriateness of accounting policies and the reasonableness of accounting estimates made by the directors[169]. - The company must disclose any significant uncertainties that may cast doubt on its ability to continue as a going concern[169]. - The auditors communicate significant audit findings, including any major deficiencies in internal controls identified during the audit[169]. - The company must ensure compliance with relevant professional ethical requirements regarding independence in its financial reporting process[171]. - The independent auditor's report is based on the audit evidence obtained up to the date of the report, and future events may affect the company's ability to continue as a going concern[169]. Corporate Social Responsibility and Sustainability - The company is committed to sustainable development and recognizes the importance of managing environmental, social, and governance-related risks[23]. - The group made charitable donations totaling HKD 208,000 during the year, along with over 24,000 product donations valued at approximately HKD 30,000[105]. - The group has implemented energy-saving measures, such as replacing traditional lighting with LED lights, to reduce greenhouse gas emissions[111]. - The company has established a sustainable development framework integrated into various levels, including the board and the Environmental, Social, and Governance (ESG) committee, ensuring all ESG goals were achieved during the year[126]. - The company recycled 5,431.80 kilograms of glass bottles this year, demonstrating effective recycling and waste reduction practices[127].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 PAK FAH YEOW INTERNATIONAL LIMITED 白 花 油 國 際 有 限 公 司 * （於百慕達註冊成立之有限公司） （股份代號：239） 二零二二年全年業績公佈 摘要 • 收入按年增加5.3%，乃歸因於醫療保健業務之銷售貢獻有所上升。 • 本集團之表現指標－基礎經常性溢利按年增加14.2%，反映醫療保健業務 表現改善。 • 報告溢利按年減少21.6%，乃由於投資物業及金融資產之未變現公平值虧 損所致，而二零二一年則錄得未變現公平值收益。 • 隨著邊境完全開放以及業務活動逐步恢復後，預計二零二三年的前景會更 明朗。 白花油國際有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，本公司及其附屬 公司（「本集團」）截至二零二二年十二月三十一日止年度之綜合經審核業績，連同 ...

Financial Performance - Revenue for the first half of 2022 decreased by 0.7% to HKD 56,202,000 compared to HKD 56,606,000 in the same period of 2021[9]. - The underlying recurring profit dropped by 37.7% to HKD 7,779,000 from HKD 12,496,000 year-on-year[9]. - The reported loss for the period was HKD 2,207,000, a significant decline from a profit of HKD 10,282,000 in the previous year[10]. - The total comprehensive loss attributable to owners for the six months ended June 30, 2022, was approximately HKD 12,418,000, compared to a profit of HKD 26,279,000 in 2021[12]. - Operating profit dropped significantly to HKD 1,189, down 91.7% from HKD 14,289 year-on-year[40]. - The group incurred a loss of HKD 2,207,000 for the period, compared to a profit of HKD 10,282,000 in the same period of the previous year[55]. - The basic and diluted loss per share for the period was HKD 0.7 cents, compared to earnings of HKD 3.3 cents in the previous year[41]. - The operating performance for the first half of 2022 showed a loss of HKD 1,189,000, a significant improvement from a loss of HKD 14,289,000 in the first half of 2021[59]. Revenue Breakdown - Healthcare segment revenue slightly decreased by 0.6% to HKD 53,055,000, while property investment revenue fell by 1.9% to HKD 3,118,000[9]. - Revenue from the healthcare segment slightly decreased by 0.6% to HKD 53,055,000, down from HKD 53,399,000 in 2021, with a profit drop of 12.7% to HKD 18,571,000[13]. - Sales in the China market declined by 7.4% to HKD 35,685,000 due to lockdowns affecting logistics and sales revenue[13]. - The North American market saw significant growth of 98.8%, with sales reaching HKD 4,623,000, up from HKD 2,325,000 in 2021[13]. Investment Properties - The loss was primarily due to unrealized fair value losses on investment properties amounting to HKD 7,101,000, compared to HKD 3,458,000 in the prior year[10]. - The unrealized fair value loss of investment properties for the period was HKD 7,101,000, compared to HKD 3,458,000 in the previous year[28]. - The valuation of investment properties in Singapore remained unchanged, while the total valuation decreased by 6.7% from HKD 285,624,000 to HKD 266,482,000 due to global economic impacts[29]. - The company recorded a net revaluation loss of HKD 3,000,000 on investment properties in Hong Kong for the first half of 2022, compared to a gain of HKD 7,300,000 in the same period of 2021[70]. Equity and Assets - Total equity decreased by 4.2% to HKD 677,852,000 from HKD 707,722,000 year-on-year[5]. - The net asset value per share fell by 4.0% to HKD 2.18 from HKD 2.27[5]. - Total assets decreased to HKD 1,390,751 as of June 30, 2022, from HKD 1,437,288 as of December 31, 2021[42]. - Non-current assets decreased to HKD 604,774 from HKD 631,310 year-on-year[42]. - The group's total assets as of June 30, 2022, amounted to HKD 823,479,000, a decrease from HKD 837,749,000 as of December 31, 2021[58]. Cash Flow and Liabilities - For the six months ended June 30, 2022, the net cash generated from operating activities was HKD 8,685,000, a significant decrease from HKD 37,511,000 in the same period of 2021, representing a decline of approximately 77.8%[48]. - The total cash and cash equivalents at the end of the reporting period increased to HKD 171,240,000 from HKD 153,321,000 year-on-year, reflecting an increase of about 11.7%[48]. - The group's liabilities totaled HKD 145,627,000 as of June 30, 2022, compared to HKD 130,027,000 at the end of 2021, indicating an increase of approximately 12%[58]. - The group reported a total of HKD 9,650,000 in accounts payable as of June 30, 2022, compared to HKD 9,280,000 as of December 31, 2021[81]. Operational Challenges and Outlook - The overall economic recovery remains unclear, with global growth slowing and inflation rising impacting the company's operations[9]. - The company remains confident in its strong fundamentals despite facing unprecedented challenges in the current environment[4]. - The company plans to enhance marketing activities in North America to capture new market segments in the second half of the year[15]. - The company plans to continue focusing on cost management and exploring new market opportunities to improve financial performance[43]. - The company plans to continue exploring market expansion opportunities and new product development strategies in the upcoming periods[63]. Corporate Governance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange listing rules and has complied with the code provisions for the six months ending June 30, 2022, except for certain deviations[108]. - The roles of the Chairman and CEO are held by the same individual, with responsibilities shared among other executive directors to maintain a balance of power[109]. - The audit committee, composed of three independent non-executive directors, reviewed the interim financial report for the six months ending June 30, 2022[110].

Financial Performance - Revenue increased by 27.9% year-on-year to HKD 139,823,000, driven by higher sales in the healthcare business[10] - Reported profit improved to HKD 38,186,000 from a loss of HKD 38,356,000 in the previous year[12] - Underlying recurring profit rose by 34.9% to HKD 35,242,000, reflecting improved performance in the healthcare segment[11] - Basic earnings per share increased to HKD 12.3, while underlying recurring earnings per share rose to HKD 11.3, up 34.5%[14] - Total comprehensive income attributable to owners was approximately HKD 55,098,000 in 2021, a significant recovery from a comprehensive loss of HKD 66,980,000 in 2020[31] - Operating profit for the year was HKD 47,489,000, compared to an operating loss of HKD 33,247,000 in the previous year[196] - Profit attributable to owners of the company for the year was HKD 38,186,000, a significant recovery from a loss of HKD 38,356,000 in 2020[196] Dividends and Shareholder Returns - Total dividend per share increased by 31.3% to HKD 8.4 from HKD 6.4[14] - The company proposed a total dividend of HKD 8.4 per share for the year, up from HKD 6.4 per share in 2020[20] - The total dividend for the year is proposed at HKD 0.084 per share, consisting of an interim dividend of HKD 0.028, a final dividend of HKD 0.038, and a special dividend of HKD 0.018[125] Market and Business Strategy - The company aims to expand existing markets while exploring new market opportunities in the short to medium term[6] - The company plans to launch its healthcare product "活絡油" in mainland China in 2022, following successful registration approval[25] - The company is investing more resources in marketing activities to expand its customer base and improve regional performance[139] Healthcare Segment Performance - Healthcare segment revenue increased by 30.0% to HKD 132,998,000 in 2021 from HKD 102,323,000 in 2020[28] - Revenue from the healthcare segment rose by 30.0% to HKD 132,998,000 in 2021, driven by a 33.3% increase in sales from China[35] Investment Properties and Financial Investments - The company’s investment properties are intended to generate stable income over the long term, providing a buffer in uncertain economic conditions[9] - The investment property segment reported a slight increase in revenue of 0.6% to HKD 6,780,000 in 2021[28] - The financial assets segment reported a significant decline in income, down 84.1% to HKD 45,000 in 2021, compared to HKD 283,000 in 2020[43] - The valuation of investment properties as of December 31, 2021, was HKD 285,624,000, a slight increase of 0.2% from HKD 285,123,000 in 2020[50] Corporate Governance - The company has adopted the new corporate governance code effective from January 1, 2022, which includes policies on anti-corruption and board independence[69] - The company is committed to maintaining a transparent and responsible corporate governance framework, adhering to the corporate governance code as per the Hong Kong Stock Exchange[68] - The board consists of three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced governance structure[70] - The company emphasizes clear communication with shareholders and adherence to the new disclosure requirements in its corporate governance report[69] Risk Management - The board is responsible for ensuring a robust and effective risk management and internal control system, recognizing that risk is inevitable but manageable to create value[104] - The risk management plan implemented during the year aims to identify, assess, manage, monitor, and report all significant risks faced by the group[105] - Regular updates on risk factors are provided to the board, with risk assessment reports covering the group's main risks and corresponding action plans[108] Employee and Training Initiatives - The group provided approximately 866.75 hours of training to employees during the year[138] - The company has established a training program for directors, ensuring continuous professional development[77] Environmental, Social, and Governance (ESG) Initiatives - The company has established a sustainable development framework integrated into various levels of the organization, including the board and the Environmental, Social, and Governance (ESG) committee[130] - The company aims to enhance its waste reduction efforts, with a target to conduct annual activities to raise employee awareness about waste reduction[133] - The group has implemented energy-saving measures, such as replacing traditional lighting with LED lights, to enhance energy efficiency and reduce greenhouse gas emissions[134] Shareholder Communication - The annual general meeting serves as a valuable opportunity for direct communication between the board and shareholders, with all resolutions passed by voting[117] - The company is committed to enhancing investor communication and has designated senior management to engage with institutional investors and analysts[118]

股份代號:239 (於百慕達 註 冊成立之有限公司) 白花油國際有限公 司＊ 2021 中期報告 本中期報告採用環保紙印製 僅供識別 ＊ | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------|-------|--------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目 錄 | | | | | | | | | | | | | | | 頁 | | | | | 公司資料 | | 2 | | | | | | | | 摘要 | | 3 | | | | | | | | 管理層討論及分析 | | | 5 | | | | ...

股份代號:239 (於百慕達 註 冊成立之有限公司) 白花油國際有限公 司＊ s 2020 年報 僅供識別 本年報採用環保紙印製 ＊ 14 & | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|----------|----------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目 錄 | | 2 | 公司資料 | | | | | | 3 | 關於我們 | | | | | | 4 | 摘要 | | | | | | | | | | | | | 5 | | 主席報告書 | | | | | 7 | | 管理層討論及分析 | | | | | 12 | | 董事會及高級管理人員 | | | | | 14 | | 企業管治報告書 | | | | | 24 | | 董事會報告書 | | | | ...

股份代號:239 (於百慕達 註 冊成立之有限公司) 白花油國際有限公 司＊ Stock Code:239 (Incorporated in Bermuda with limited liability) PAK FAH YEOW INTERNATIONAL LIMITED This Interim Report is printed on environmentally friendly paper 2020中期報告 2020INTERIM REPORT 僅供識別 本中期報告採用環保紙印製 ＊ 目 錄 頁 公司資料 2 摘要 3 管理層討論及分析 5 簡明中期財務資料的獨立核數師審閱報告 14 簡明綜合全面收益表 16 簡明綜合財務狀況表 18 簡明綜合權益變動表 20 簡明綜合現金流量表 21 簡明中期財務資料註釋 22 權益披露及其他資料 38 公司資料 二 零 二 零 年 中 期 報 告 白 花 油 國 際 有 限 公 司 2 | --- | --- | |-------------------------------------------|----------------------------- ...

Revenue and Profit Performance - Revenue increased by 4.8% year-on-year to HKD 147,761,000, driven by higher sales in the healthcare business[9] - Underlying recurring profit rose by 33.4% to HKD 35,566,000, reflecting improved performance in healthcare products, particularly in Hong Kong and Macau[9] - Reported profit decreased by 3.3% to HKD 36,046,000, primarily due to fair value losses on investment properties[10] - Basic earnings per share for reported profit fell to HKD 11.6, a decrease of 3.3%[12] - Basic recurring earnings per share increased by 32.6% to HKD 11.4[12] - Total revenue for the group in 2019 was HKD 147,800,000, representing a year-on-year increase of 4.8%[21] - The underlying recurring profit increased by 33.4% to HKD 35,600,000, primarily due to improved performance in the healthcare products business, particularly in Hong Kong and Macau[21] - The reported profit for 2019 decreased by 3.3% to HKD 36,000,000, mainly due to unrealized fair value losses on investment properties[21] - The healthcare segment's revenue for 2019 was HKD 136,611,000, up 4.3% from HKD 130,962,000 in 2018[31] - Revenue from Hong Kong increased by 19.4% to HKD 79,968,000, while revenue from mainland China decreased by 44.8% to HKD 11,393,000[36] Dividends and Shareholder Equity - Total dividend per share increased by 4.3% to HKD 10.80[12] - The company proposed a final dividend of HKD 0.038 per share, maintaining the same level as the previous year, resulting in a total dividend of HKD 0.108 per share for 2019[22] - Shareholders' equity rose by 0.5% to HKD 760,117,000[12] - The total dividend for the year is proposed at HKD 10.8 per share, consisting of an interim dividend of HKD 0.07 and a final dividend of HKD 0.038[123] Market Strategy and Growth - The company aims to expand existing markets while seeking opportunities in new markets for its healthcare products[5] - Long-term growth strategy includes investing in brand building and market share despite an uncertain outlook for 2020[11] - The company aims to maintain growth while continuing to invest in brand building and market share as part of its long-term growth strategy[28] Investment Properties and Financial Management - The company’s investment properties are intended to generate stable income over the long term, providing a buffer in uncertain economic conditions[8] - The fair value loss on investment properties at year-end 2019 amounted to HKD 1,400,000, compared to a gain of HKD 11,500,000 in 2018[23] - The group's investment properties were valued at HKD 346,432,000 as of December 31, 2019, a slight increase of 0.8% from HKD 343,731,000 in 2018[50] - The debt-to-equity ratio was 2.6% as of December 31, 2019, down from 2.9% in 2018, with total bank borrowings amounting to HKD 19,492,000[51] - The current ratio improved to 3.31 times as of December 31, 2019, compared to 2.81 times in 2018, indicating sufficient liquidity to meet short-term obligations[51] Risk Management and Corporate Governance - The board is responsible for ensuring compliance with legal and regulatory requirements[73] - The company has adopted all code provisions of the Corporate Governance Code as set out in the Listing Rules, demonstrating commitment to transparency and accountability[66] - The company’s governance structure includes a mix of professionals with expertise in accounting, finance, and law, contributing to informed decision-making[67] - The board is responsible for ensuring a robust risk management and internal control system, with the audit committee assisting in this responsibility[99] - The risk management plan aims to ensure all significant risks are properly identified, assessed, managed, monitored, and reported to the audit committee and the board[100] Employee and Training Initiatives - The total number of employees was 90 as of December 31, 2019, a slight decrease from 91 in 2018[56] - The company provided around 334 hours of training to employees during the year, emphasizing its commitment to workforce development[134] Environmental, Social, and Governance (ESG) Commitments - The company has established an Environmental, Social, and Governance (ESG) committee to oversee its environmental policies and performance[128] - The group has implemented various energy-saving measures, including replacing traditional lighting with LED lights, to reduce carbon emissions[131] - The company has designed and implemented a self-assessment and evaluation plan for all suppliers to manage environmental and social risks in the supply chain[140] Audit and Financial Reporting - The independent auditor's report was issued on March 26, 2020, by the auditing firm Zhongzheng CPA (Hong Kong) Limited[194] - The company’s financial statements for the year ended December 31, 2019, were audited and deemed to fairly reflect the financial position and performance of the group[180] - The auditors aim to obtain reasonable assurance that the financial statements are free from material misstatement due to fraud or error[190]